Budget impact of niraparib as maintenance treatment in recurrent ovarian cancer following platinum-based chemotherapy. (2nd April 2019)

• Record Type: Journal Article
• Authors: Neeser, Kurt; O'Neil, William M; Stern, Lee; Harrow, Brooke; Travers, Karin
• Is Part Of: Journal of comparative effectiveness research. Volume 8:Number 8(2019)
• Page Start: 577
• Page End: 587
• Publication Date: 2019-04-02
• Subjects: budget impact analysis -- costs -- economics -- maintenance therapy -- PARP inhibitors -- recurrent ovarian cancer -- USA; Medical care -- Research -- Periodicals; Medical care -- Research -- Evaluation -- Periodicals; Medical care -- Decision making -- Periodicals; Evidence-based medicine -- Periodicals; Medicine, Comparative -- Periodicals; 362.1072
• DOI: 10.2217/cer-2018-0069
• Languages: English
• ISSNs: 2042-6305

Abstract

Aim: To estimate financial implications of adopting niraparib as maintenance treatment in recurrent ovarian cancer.Materials & methods: A model was developed to estimate the budget impact of treating patients with niraparib compared with alternative maintenance treatment options (olaparib, rucaparib, bevacizumab or 'watch and wait') over 3 years.Results: For a hypothetical plan with 1 million lives representative of US/Medicare-only populations, projected cost savings with niraparib were US$78, 721/$293, 723, $276, 671/$1, 009, 729 and $353, 585/$1, 289, 712 at years 1, 2 and 3, respectively. Sensitivity analyses showed prices of niraparib, rucaparib and olaparib to have the most significant impact on the budget.Conclusion: Factoring in all treatment-related costs, the use of niraparib could result in significant cost savings compared with other maintenance treatment options.